Literature DB >> 1696938

Epitopes of Escherichia coli alpha-hemolysin: identification of monoclonal antibodies that prevent hemolysis.

G E Ji1, P O'Hanley.   

Abstract

The antigenic regions of Escherichia coli alpha-hemolysin were determined by antibody binding to cyanogen bromide (CnBr) fragments of this protein under denatured conditions. Alpha-hemolysin was isolated from filtered culture supernatants of a recombinant strain by a combination of trichloroacetic acid precipitation and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Alpha-hemolysin was used to (i) produce polyclonal rabbit antisera and murine monoclonal immunoglobulin G (IgG) antibodies and (ii) generate CnBr fragments. Rabbit IgG and 13 murine IgG monoclonal antibodies (MAbs) were elicited to alpha-hemolysin as determined by enzyme-linked immunosorbent and immunoprecipitation assays. Antibodies bound to three specific CnBr fragments of alpha-hemolysin in Western blots (immuno-blots) from sodium dodecyl sulfate-polyacrylamide gels: CnBrII (encompassing residues [R] 2 to 160), CnBrV (R 425 to 892), and CnBrVI (R 893 to 1023). Five MAbs bound to CnBrII, seven MAbs bound to CnBrV, and one MAb bound to CnBrVI. These specific CnBr fragments are predicted to be hydrophilic and charged. There was no antibody binding to the highly hydrophobic CnBrIII (R 161 to 416). Similar binding patterns were observed when rabbit polyclonal anti-alpha-hemolysin IgG was used. Polyclonal antibodies to alpha-hemolysin readily inhibited hemolysis and its neutralization capacity was 4- to 64-fold more potent than neutralizing MAbs. The five MAbs that bind to CnBrII possessed hemolytic neutralizing activity to various degrees. In contrast, only three of seven MAbs that bind to CnBrV fragment exhibited neutralization capacity to various degrees; the MAb to CnBrVI did not exhibit this capacity. Based on these data, we predict that denatured alpha-hemolysin and its CnBrII and CnBrV fragments might be worthwhile immunoprophylactic candidates for the prevention of hemolysin-mediated E. coli tissue injury.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696938      PMCID: PMC313606          DOI: 10.1128/iai.58.9.3029-3035.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Nonenzymatic cleavage of peptide bonds: the methionine residues in bovine pancreatic ribonuclease.

Authors:  E GROSS; B WITKOP
Journal:  J Biol Chem       Date:  1962-06       Impact factor: 5.157

2.  Genetical and functional organisation of the Escherichia coli haemolysin determinant 2001.

Authors:  N Mackman; J M Nicaud; L Gray; I B Holland
Journal:  Mol Gen Genet       Date:  1985

3.  Escherichia coli haemolysin forms voltage-dependent ion channels in lipid membranes.

Authors:  G Menestrina; N Mackman; I B Holland; S Bhakdi
Journal:  Biochim Biophys Acta       Date:  1987-11-27

4.  The antigenic index: a novel algorithm for predicting antigenic determinants.

Authors:  B A Jameson; H Wolf
Journal:  Comput Appl Biosci       Date:  1988-03

5.  Quantitative study of the binding and hemolytic efficiency of Escherichia coli hemolysin.

Authors:  B Eberspächer; F Hugo; S Bhakdi
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

6.  Pore formation by the Escherichia coli hemolysin: evidence for an association-dissociation equilibrium of the pore-forming aggregates.

Authors:  R Benz; A Schmid; W Wagner; W Goebel
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

7.  The repeat domain of Escherichia coli haemolysin (HlyA) is responsible for its Ca2+-dependent binding to erythrocytes.

Authors:  A Ludwig; T Jarchau; R Benz; W Goebel
Journal:  Mol Gen Genet       Date:  1988-11

8.  Gal-Gal binding and hemolysin phenotypes and genotypes associated with uropathogenic Escherichia coli.

Authors:  P O'Hanley; D Low; I Romero; D Lark; K Vosti; S Falkow; G Schoolnik
Journal:  N Engl J Med       Date:  1985-08-15       Impact factor: 91.245

9.  Transcriptional organization of the Escherichia coli hemolysin genes.

Authors:  R A Welch; S Pellett
Journal:  J Bacteriol       Date:  1988-04       Impact factor: 3.490

10.  Alterations of amino acid repeats in the Escherichia coli hemolysin affect cytolytic activity and secretion.

Authors:  T Felmlee; R A Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

View more
  8 in total

1.  Characterization of monoclonal antibodies against alpha-hemolysin of Escherichia coli.

Authors:  R L Oropeza-Wekerle; P Kern; D Sun; S Muller; J P Briand; W Goebel
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

Review 2.  The different hemolysins of Escherichia coli.

Authors:  L Beutin
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

3.  Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.

Authors:  P O'Hanley; G Lalonde; G Ji
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

4.  Characterization of hemolysin of Moraxella bovis using a hemolysis-neutralizing monoclonal antibody.

Authors:  F M Billson; C Harbour; W P Michalski; J M Tennent; J R Egerton; J L Hodgson
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

5.  Binding of Pasteurella haemolytica leukotoxin to bovine leukocytes.

Authors:  J F Brown; F Leite; C J Czuprynski
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

6.  Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis.

Authors:  John A Angelos; V Michael Lane; Louise M Ball; John F Hess
Journal:  Vet Res Commun       Date:  2010-03-10       Impact factor: 2.459

7.  Genetic conservation of hlyA determinants and serological conservation of HlyA: basis for developing a broadly cross-reactive subunit Escherichia coli alpha-hemolysin vaccine.

Authors:  P O'Hanley; R Marcus; K H Baek; K Denich; G E Ji
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

8.  Characterization of a neutralizing monoclonal antibody to Pasteurella haemolytica leukotoxin.

Authors:  D G Gerbig; M R Cameron; D K Struck; R N Moore
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.